Anaplastic lymphoma kinase-positive large B-cell lymphoma: Description of a case with an unexpected clinical outcome

International Journal of Surgical Pathology

Volumn 23, Issue 1, 2015, Pages 78-83

  Zanelli, Magda ^a   Valli, Riccardo ^a   Capodanno, Isabella ^a   Ragazzi, Moira ^a   Ascani, Stefano ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

ALK positivity; ALK positive large B cell lymphoma; Anaplastic lymphoma kinase (ALK); Immunohistochemistry; Large B cell lymphoma; t(2; 17)

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; ORGANIC CATION TRANSPORTER 2; SYNDECAN 1; VINCRISTINE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HUMANS; IFOSFAMIDE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; TREATMENT OUTCOME; VINCRISTINE;

EID: 84920859569     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896914536223     Document Type: Article

References (23)

1. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood. 1997;89:1483-1490.
2. Beltran B, Castillo J, Salas R, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009;2:11.
3. De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood. 2003;102:2638-2641.
4. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102:2568-2573.
5. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27:4211-4216.
6. Li K, Tipps AM, Wang HY. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. Int J Clin Exp Pathol. 2011;4:190-196.
7. Li S. Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol. 2009;2:508-518.
8. Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102:2642-2644.
9. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007;20:310-319.
10. Sellami-Dhouib R, Nasfi A, Mejri NT, et al. Ovarian ALK+ diffuse large B-cell lymphoma: a case report and a review of the literature. Int J Gynecol Pathol. 2013;32:471-475.
11. Zhang D, Denley RC, Filippa DA, Teruya-Feldstein J. ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23). Appl Immunohistochem Mol Morphol. 2009;17:172-177.
12. Stachurski D, Miron PM, Al-Homsi S, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24. Hum Pathol. 2007;38:940-945.
13. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
14. Swerdlow SH, Jaffe ES, International Agency for Research on Cancer, World Health Organization, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
15. Morgan EA Nascimento AF. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol. 2012;2012:529572.
16. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254-263.
17. Lindeman NI, Cagle PT, Beasley MB, et al; College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415-453.
18. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686-694.
19. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16:802-810.
20. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736-747.
21. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
22. Cerchietti L, Damm-Welk C, Vater I, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One. 2011;6:e18436.
23. Wass M, Behlendorf T, Schädlich B, et al. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2014;92:268-270.